Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3


  1. Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.

    Article  PubMed  Google Scholar 

  2. Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314–11322.

    Article  CAS  PubMed  Google Scholar 

  3. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469–471.

    Article  CAS  PubMed  Google Scholar 

  4. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477–485.

    Article  CAS  PubMed  Google Scholar 

  5. Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681.

    Article  CAS  PubMed  Google Scholar 

  6. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–1766.

    CAS  PubMed  Google Scholar 

  7. Apperley J . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018–1029.

    Article  CAS  PubMed  Google Scholar 

  8. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007; 109: 2112–2120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064–4072.

    Article  CAS  PubMed  Google Scholar 

Download references


This work was funded by AIRC, EU (LSHB-CT-2004-503467), MIUR-PRIN program (2008), Ministry of health–Integrated program of oncology (RFPS-2006-2-333974).

Author information

Authors and Affiliations


Ethics declarations

Competing interests

Dr Frank Boschelli is employee at Pfizer Research, which is developing bosutinib for treatment of CML. No other conflict of interest to disclose.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Redaelli, S., Boschelli, F., Perini, P. et al. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia 24, 1223–1227 (2010).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links